LCZ696 in Advanced LV Hypertrophy and HFpEF

Heart Failure Clinical Trial

Official title: Sacubitril/Valsartan (LCZ696) in Patients With Advanced Hypertensive Left Ventricular Hypertrophy and Heart Failure With Preserved Ejection Fraction: Clinical, Haemodynamic and Neurohumoral Effects (a Phase 2, Randomized, Single-center, Parallel Group Study)

Status Recruiting

Clinical Trial Summary

Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.

Clinical Trial Description

Heart failure with preserved ejection fraction (HFpEF) has a significant morbidity and mortality, and therapies that have proven effective in HF with reduced EF have not been shown to improve long-term prognosis in HFpEF. Inhibition of circulating neprilysin could augment deficient NP-receptor GC signaling and therefore be beneficial in HFpEF, as suggested by the decrease in NP following administration of valsartan/sacubitril in the phase 2 (PARAMOUNT study). Use of valsartan/sacubitril is currently being tested in the multicenter PARAGON-HF trial with HFpEF patients. The investigators suppose the best candidates for LCZ696 therapy will be patients with HFpEF and advanced concentric LV hypertrophy and obesity, i.e. having the lowest BNP bioavailability. ;

Related Conditions & MeSH terms

• Essential Hypertension
• Heart Failure
• Hypertrophy

• NCT number: NCT03928158
• Study type: Interventional
• Source: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
• Contact: Artem Ovchinnikov, MD, PhD
• Phone: +74954146612
• Email: artcardio@mail.ru
• Status: Recruiting
• Phase: Phase 2
• Start date: May 31, 2019
• Completion date: November 30, 2022